Crenigacestat
Cat. No.：YN380062
CAS No. ：1421438-81-4
| 产品名称: | Crenigacestat |
| CAS No.: | 1421438-81-4 |
| Chemical Name: | N-[(1S)-2-[[(7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-butanamide |
| Synonyms: | LY3039478 |
| 分子量: | 464.44 |
| 分子式: | C₂₂H₂₃F₃N₄O₄ |
| SMILES: | O=C(N[C@@H](C)C(N[C@H]1C2=CC=CC=C2C3=CC=CN=C3N(CCO)C1=O)=O)CCC(F)(F)F |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Crenigacestat (LY3039478) 是具有口服活性的Notch和γ-secretase的抑制剂，其在多种肿瘤细胞中的IC50为 ∼1nM。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Yuen, E., Posada, M., Smith, C., et al.Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjectsCancer Chemother. Pharmacol.83(3),483-492(2019)
Bhagat, T.D., Zou, Y., Huang, S., et al.Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancerJ. Biol. Chem.292(3),837-846(2017)
